Comparative Pharmacology
Head-to-head clinical analysis: ISOPROTERENOL HYDROCHLORIDE versus VAPO ISO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOPROTERENOL HYDROCHLORIDE versus VAPO ISO.
ISOPROTERENOL HYDROCHLORIDE vs VAPO-ISO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-adrenergic agonist with non-selective affinity for β1 and β2 receptors; increases myocardial contractility, heart rate, and bronchodilation via Gs-protein activation and cAMP elevation.
VAPO-ISO (isoproterenol) is a non-selective beta-adrenergic agonist that stimulates both beta-1 and beta-2 adrenergic receptors. It increases heart rate, contractility, and conduction velocity (beta-1), and causes bronchodilation and peripheral vasodilation (beta-2).
Initial IV infusion: 0.5-5 mcg/min, titrated to heart rate and blood pressure; typical range 2-10 mcg/min. IV bolus: 10-20 mcg as needed. Continuous infusion: 0.01-0.5 mcg/kg/min (max 30 mcg/min).
Inhalation: 1-2 inhalations of a 0.5% solution for acute bronchospasm; 0.5 mL of 1:200 solution via nebulizer every 4-6 hours as needed.
None Documented
None Documented
Terminal elimination half-life is 2-3 minutes; clinically, catechol-O-methyltransferase (COMT)-mediated metabolism leads to rapid clearance.
Terminal elimination half-life is 2–4 hours (mean 3 hours). In severe renal impairment (CrCl <30 mL/min), half-life may be prolonged to 8–12 hours, requiring dose adjustment.
Primarily renal excretion of sulfate conjugates and unchanged drug; biliary/fecal excretion is minimal.
Renal excretion of unchanged drug (30–50%) and hepatic metabolism to inactive metabolites. Fecal excretion is negligible (<2%).
Category C
Category C
Beta-Adrenergic Agonist
Beta-Adrenergic Agonist